Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,980 matching trials from the live ClinicalTrials.gov search.
Filters: San Diego, California Clear all
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

NCT02240238
View directory record Official record
Conditions
Solid Tumors
Interventions
NC-6004, Gemcitabine
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
10
States / cities
Encinitas, California • La Jolla, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 29, 2026, 5:16 PM EDT
Terminated Phase 3 Interventional

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

NCT00072215
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
cisplatin, ifosfamide, paclitaxel, vinblastine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
78
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

NCT01903811
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
485
States / cities
Fairbanks, Alaska • Tucson, Arizona • Anaheim, California + 318 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 29, 2026, 5:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT02466971
View directory record Official record
Conditions
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
377
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction

NCT04406584
View directory record Official record
Conditions
Olfactory Disorder, Olfaction Disorders, Olfactory Nerve Injuries, Olfactory Nerve Disorder, Olfactory Nerve Diseases, Covid19, Post-Viral Disorder
Interventions
Injection into olfactory cleft
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Diego, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 29, 2026, 5:16 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

NCT01917006
View directory record Official record
Conditions
Premature Ejaculation
Interventions
OnabotulinumtoxinA, Normal Saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Diego, California • Torrance, California • Middlebury, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 29, 2026, 5:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Using Mobile Health Applications for Health

NCT05589155
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Mobile health application
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 29, 2026, 5:16 PM EDT
Completed No phase listed Observational

Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

NCT05309382
View directory record Official record
Conditions
Heart Transplant
Interventions
Prospera
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Not applicable Interventional

ASD Wearables Feasibility Study

NCT07504224
View directory record Official record
Conditions
Autism Spectrum Disorder, Wearable Devices
Interventions
14-Day Device Monitoring
Device
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

NCT05951023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone 2 mg, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 5:16 PM EDT
Recruiting Phase 1 Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT04485559
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions
Everolimus, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 29, 2026, 5:16 PM EDT
Withdrawn Not applicable Interventional

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Knee Surgery

NCT07336355
View directory record Official record
Conditions
Knee Arthropathy
Interventions
Percutaneous peripheral nerve stimulation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Not applicable Interventional

Treating Pediatric NAFLD with Nutrition

NCT05499585
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
Interventions
Whole Dairy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

NCT02423343
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
Interventions
Galunisertib, Nivolumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

NCT01007435
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
61
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 1 Interventional Results available

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017
View directory record Official record
Conditions
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions
Cabiralizumab, Nivolumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 29, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

NCT00300950
View directory record Official record
Conditions
Pancreas Cancer
Interventions
GI-4000, Gemcitabine
Biological · Drug
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 29, 2026, 5:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
NRTX-1001
Biological
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 5:16 PM EDT